Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Sells $172,567.26 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,637 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the sale, the chief financial officer now directly owns 73,849 shares in the company, valued at $1,475,503.02. This trade represents a 10.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Kory James Wentworth also recently made the following trade(s):

• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.97, for a total value of $47,829.15.

Entrada Therapeutics Stock Down 6.2 %

NASDAQ TRDA opened at $17.85 on Friday. Entrada Therapeutics, Inc. has a fifty-two week low of $10.75 and a fifty-two week high of $20.49. The business has a fifty day moving average of $16.76 and a 200-day moving average of $15.92. The stock has a market cap of $667.95 million, a price-to-earnings ratio of 11.23 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The firm had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of TRDA. US Bancorp DE purchased a new stake in Entrada Therapeutics in the 3rd quarter worth approximately $42,000. Acadian Asset Management LLC purchased a new position in Entrada Therapeutics during the first quarter worth about $79,000. SG Americas Securities LLC acquired a new stake in Entrada Therapeutics in the 3rd quarter worth about $156,000. Allspring Global Investments Holdings LLC boosted its stake in Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after buying an additional 11,965 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Entrada Therapeutics by 34.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after buying an additional 3,644 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. HC Wainwright lifted their price target on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Oppenheimer upped their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.